Vlad Coric, M.D., CEO of Biohaven Pharmaceuticals, joins Venrock partner Nimish Shah to speak about the significance of innovation and creativity across all aspects of a business. Coric dives into the challenges of launching Biohaven’s drug, Nurtec ODT, during the pandemic and why he believed it was their moral duty to continue the drug supply chain, despite the lockdown. Still seeing patients today, Coric discusses how his patient-centric approach positively guided him as a drug developer. Coric touches on Biohaven’s collaboration with Khloe Kardashian for Nurtec’s launch and his excitement for the digital transformation occurring in biotech. Coric also advises other biotech CEOs raising a cross-over round or going public to be selective with the investors they invite in, as they become an extension of the team.

  • Subscribe:

Want more? Here’s the latest on Running Through Walls.

Farzad Mostashari, founder and CEO of Aledade, speaks with Venrock’s Bryan Roberts and Bob Kocher about improving the quality and efficiency of patient care with a focus on preventative care. With the recent launch of Aledade Care Solutions and new focus on Medicare Advantage, Mostashari delves into Aledade’s efforts to scale and deliver where average primary care practices can’t. Mostashari also reveals his approach to value based care incentive structure, and why building a valuable solution requires a long time horizon.
  1. Thinking Long Term is the Greatest Gift
  2. Diversifying the Cap Table
  3. The Balancing Act of Drug Discovery
  4. Bust the Liars Without Elevating the Liars
  5. Healthy Skepticism in Product Management